Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
40.11 USD | +2.19% | -1.23% | -32.99% |
May. 31 | Piper Sandler Starts Apellis Pharmaceuticals With Neutral Rating, $46 Price Target | MT |
May. 24 | Apellis Pharmaceuticals, Sobi Say Pegcetacoplan Reduces Post-Transplant Kidney Diseases | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.99% | 4.87B | |
-1.33% | 90.85B | |
-1.05% | 39.02B | |
-11.20% | 33.46B | |
+61.85% | 26.38B | |
-20.75% | 14.51B | |
-6.35% | 13.22B | |
-11.42% | 11.65B | |
-47.67% | 10.57B | |
+5.99% | 9.23B |
- Stock Market
- Equities
- APLS Stock
- News Apellis Pharmaceuticals, Inc.
- Apellis Pharmaceuticals : Needham Adjusts Price Target on Apellis Pharmaceuticals to $85 From $65, Reiterates Buy Rating